Dhodapkar Meera M, Halperin Scott J, Day Wesley, Saifi Comron, Rubio Daniel R, Koumpouras Fotios, Grauer Jonathan N, Varthi Arya
Yale School of Medicine, Department of Orthopaedics and Rehabilitation, 47 College St, New Haven, CT 06510, United States.
Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, United States.
N Am Spine Soc J. 2025 Mar 13;22:100604. doi: 10.1016/j.xnsj.2025.100604. eCollection 2025 Jun.
Posterior lumbar fusion (PLF) is a common procedure, for which patients with systemic conditions may be considered. Autoimmune conditions, such as lupus are 1 such class of conditions and include systemic lupus erythematosus (SLE) and discoid lupus erythematosus (DLE).
To characterize outcomes following single-level PLF in patients with SLE and DLE.
STUDY DESIGN/SETTING: Retrospective study.
Adult patients without and with SLE or DLE who underwent single-level PLF with or without interbody fusion from 2010 to 2021 Q1 PearlDiver Database were identified and separately matched 4:1 based on age, sex and Elixhauser Comorbidity Index. Exclusion criteria included: age < 18 years, recent history of infection, neoplasm, or trauma, as well as database inactivity within 90 days postoperatively.
Ninety-day postoperative adverse events and readmission rates.
Univariable analyses and multivariable logistic regression of postoperative adverse events and readmission rates.
Overall, 191,765 patients who underwent PLF between 2010 and 2021 Q1 and met inclusion criteria were identified, of which 2,068 (1.1%) had a diagnosis of SLE and 242 (0.1%) had a diagnosis of DLE. On multivariable analysis of the matched populations, patients with SLE were at most increased odds of 90-day (in decreasing ORs): pneumonia (OR 4.45), urinary tract infection (OR 4.24), minor adverse events (OR 3.17), all adverse events (OR 2.78), deep vein thrombosis (OR 2.71), acute kidney injury (OR 2.62), transfusion (OR 2.08), pulmonary embolism (OR 1.98), sepsis (OR 1.66), surgical site infection (OR 1.29) (p<.0033 for all). Patients with SLE were not at increased odds of 90-day re-admissions or wound dehiscence (p>.0033 for both). On multivariable analysis, patients with DLE were only at increased odds of 90-day all adverse events (OR 1.83) and minor adverse events (OR 1.77) (p<.0033 for all).
The current study examined the largest to our knowledge cohort of SLE and DLE patients undergoing PLF. Patients with these conditions were at greater odds of several perioperative adverse outcomes.
腰椎后路融合术(PLF)是一种常见的手术,患有全身性疾病的患者也可考虑接受该手术。自身免疫性疾病,如狼疮就是这类疾病之一,包括系统性红斑狼疮(SLE)和盘状红斑狼疮(DLE)。
描述SLE和DLE患者单节段PLF后的结局。
研究设计/地点:回顾性研究。
从PearlDiver数据库中识别出2010年至2021年第一季度接受单节段PLF(伴或不伴椎间融合)的成年患者,包括无SLE或DLE的患者以及患有SLE或DLE的患者,并根据年龄、性别和埃利克斯豪泽合并症指数按4:1分别进行匹配。排除标准包括:年龄<18岁、近期有感染、肿瘤或创伤史,以及术后90天内数据库无活动记录。
术后90天不良事件和再入院率。
对术后不良事件和再入院率进行单变量分析和多变量逻辑回归分析。
总体而言,共识别出191,765例在2010年至2021年第一季度接受PLF且符合纳入标准的患者,其中2,068例(1.1%)诊断为SLE,242例(0.1%)诊断为DLE。在对匹配人群的多变量分析中,SLE患者在90天内发生以下情况的几率最高(按比值比降序排列):肺炎(比值比4.45)、尿路感染(比值比4.24)、轻微不良事件(比值比3.17)、所有不良事件(比值比2.78)、深静脉血栓形成(比值比2.71)、急性肾损伤(比值比2.62)、输血(比值比2.08)、肺栓塞(比值比1.98)、败血症(比值比1.66)、手术部位感染(比值比1.29)(所有p<.0033)。SLE患者90天再入院或伤口裂开的几率没有增加(两者p>.0033)。在多变量分析中,DLE患者仅90天内所有不良事件(比值比1.83)和轻微不良事件(比值比1.77)的几率增加(所有p<.0033)。
据我们所知,本研究调查了接受PLF的SLE和DLE患者的最大队列。患有这些疾病的患者围手术期发生多种不良结局的几率更高。